|
Syncona Ltd on Monday noted that its portfolio company Anaveon AG received ‘encouraging’ first clinical data from its ongoing phase I/II study for ANV419.
Anaveon is a Basel, Switzerland-based clinical-stage immuno-oncology firm. It is currently developing ANV419, which is an immunotherapy for cancer.
The London-based investment trust focused on healthcare said 16 patients across seven dosing cohorts with different types of progressing cancer had received ANV419.
Syncona stated that ANV419 has shown to be well-tolerated, with ‘highly favourable’ safety data.
Based on the ‘encouraging’ data from the phase I/II programme, a phase II study of ANV419 in multiple tumour types has been initiated.
Shares in Syncona were down 0.7% at 165.80 pence in London on Monday.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
